Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27270574 | 0.79 | AR (0.38) | ARLRRK2CDK1KDRALDH1A1 | |
| SCHEMBL13058728 | 0.79 | ALDH1A1 (0.36) | ARLRRK2CDK1KDRMEN1 | |
| SCHEMBL21709820 | 0.78 | ALDH1A1 (0.35) | CDK1KDRMEN1KMT2AALDH1A1 | |
| SCHEMBL22096837 | 0.78 | EGLN2 (0.36) | ARLRRK2CDK1KDRALDH1A1 | |
| SCHEMBL22096839 | 0.78 | CDK1 (0.35) | ARLRRK2CDK1KDRMEN1 | |
| SCHEMBL13074742 | 0.75 | LRRK2 (0.40) | ARLRRK2MEN1KMT2AALDH1A1 | |
| SCHEMBL10220663 | 0.74 | AXL (0.32) | — | |
| SCHEMBL846091 | 0.74 | LRRK2 (0.42) | ARLRRK2MEN1KMT2AALDH1A1 | |
| SCHEMBL30007698 | 0.74 | LRRK2 (0.42) | ARLRRK2MEN1KMT2AALDH1A1 | |
| SCHEMBL13058512 | 0.74 | CDK1 (0.31) | CDK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273080-B2 | Metal complexes | MEREK PATENT GMBH (DE) | 2016-03-01 | — | — | US | disclosed |
| US-8716303-B2 | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130082209-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2013-04-04 | — | — | US | disclosed |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | AR 3732/4885LRRK2 1432/4885CDK1 57/4885 |
| US-20130082209-A1 | METAL COMPLEXES | MCOLN2, MCOLN1, AP1M1 | AR 3642/4885LRRK2 308/4885CDK1 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.